Last reviewed · How we verify
Routine biological monitoring
Routine biological monitoring is a Biologic drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development.
At a glance
| Generic name | Routine biological monitoring |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Cognitive Assessment And Post-Operative Complications After Surgery: Linking Anaesthesia And Risk
- A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
- Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and/or Refractory Thin Endometrium (NA)
- Proactive TDM Versus Standard Use of Biologics in Psoriasis (PHASE4)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
- Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients (PHASE3)
- Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Routine biological monitoring CI brief — competitive landscape report
- Routine biological monitoring updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Routine biological monitoring
What is Routine biological monitoring?
Routine biological monitoring is a Biologic drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes Routine biological monitoring?
Routine biological monitoring is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
What development phase is Routine biological monitoring in?
Routine biological monitoring is in Phase 2.